Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a report issued on Monday. The firm issued a sell rating on the stock.

Oragenics Price Performance

Shares of OGEN stock opened at $0.31 on Monday. The company has a market cap of $1.74 million, a PE ratio of -0.04 and a beta of 0.49. Oragenics has a 1 year low of $0.28 and a 1 year high of $7.74. The stock’s 50 day simple moving average is $0.46 and its two-hundred day simple moving average is $1.06.

Oragenics (NYSE:OGEN) last released its quarterly earnings results on Friday, August 9th. The company reported ($0.51) earnings per share for the quarter.

Institutional Trading of Oragenics

A hedge fund recently bought a new stake in Oragenics stock. Virtu Financial LLC bought a new position in Oragenics, Inc. (NYSE:OGEN) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 22,675 shares of the company’s stock, valued at approximately $33,000. Virtu Financial LLC owned 0.51% of Oragenics as of its most recent SEC filing. 18.71% of the stock is owned by hedge funds and other institutional investors.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.